Cargando…

Inflammatory bowel disease of the lung: The role of infliximab?()

Pulmonary extra-intestinal manifestations (EIM) of inflammatory bowel disease are well described with a variable incidence. We present a case of Crohn's disease with pulmonary EIM including chronic bronchitis with non-resolving bilateral cavitary pulmonary nodules and mediastinal lymphadenopath...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayek, Adam J., Pfanner, Timothy P., White, Heath D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501542/ https://www.ncbi.nlm.nih.gov/pubmed/26236612 http://dx.doi.org/10.1016/j.rmcr.2015.05.012

Ejemplares similares

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease
por: Matsueda, Katsunori, et al.
Publicado: (2018)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Pneumococcal Vaccination Rates in VHA Patients With Inflammatory Bowel Disease
por: Case, David J., et al.
Publicado: (2015)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

The role of latanoprost in an inflammatory bowel disease flare
por: Paul, Sonali, et al.
Publicado: (2014)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
por: Ning, Longui, et al.
Publicado: (2019)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease
por: Hellmann, Jennifer, et al.
Publicado: (2021)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update
por: Guo, Yuan, et al.
Publicado: (2013)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
por: Loveikyte, Roberta, et al.
Publicado: (2023)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
por: Bernard, Edmond-Jean, et al.
Publicado: (2020)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis
por: Kaddoura, Rachid, et al.
Publicado: (2023)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ide7lo2ublhv50qmpp1j8o2lp5